– INXN-4001 delivered via retrograde coronary sinus infusion was well-tolerated in patients with chronic heart failure – – Preliminary data suggest an overall improvement in patient reported outcomes in 50% of patients six months after treatment – GERMANTOWN, Md., Aug. 6, 2020 /PRNewswire/ — Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company […]